Thursday – Basic Science Track 1B Survey

Full Name(Required)
Enter your first and last names as you would like them to appear on your certificates.
Enter the email you used to register for TOXINS 2022.

Please evaluate the speakers

Topic and Speaker(s)
ExcellentGoodFairPoor
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1
Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins
Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far
K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction
Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition
Geoffrey Masuyer, PhD (Sweden)
YesNo
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1
Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins
Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far
K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction
Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition
Geoffrey Masuyer, PhD (Sweden)
YesNo
Cryo-EM structures of the 300 kDa progenitor toxin complexes of BoNT/B, BoNT/X, BoNT/Wo and PMP1
Pål Stenmark, PhD (Sweden)
Receptor-binding mechanism of botulinum neurotoxins
Rongsheng Jin, PhD (USA)
Lessons learnt from the structural aspects of botulinum neurotoxin research so far
K. Ravi Acharya, PhD (UK)
Excitation-contraction-coupling inhibitors potentiate the activity of botulinum neurotoxin type A at the neuromuscular junction
Mickaël Machicoane, PhD (Switzerland)
Structure-based design of a botulinum neurotoxin with triple receptor recognition
Geoffrey Masuyer, PhD (Sweden)
Strongly disagreeDisagreeNeutralAgreeStrongly agree
Ability to evaluate the latest clinical and scientific research into botulinum neurotoxins
Understanding of the clinical utility of botulinum neurotoxins
Understanding of potential new therapeutic applications of botulinum neurotoxins
Biomedical knowledge of botulinum and other neurotoxins and their application in enhancing therapeutics and improving care